TOPIC : Osteoarticular tissues regeneration (RIA)
|Publication date:||27 October 2017|
|Types of action:||RIA Research and Innovation action|
|DeadlineModel: Opening date:||two-stage 31 October 2017||Deadline: 2nd stage Deadline:||
23 January 2018 17:00:00
28 June 2018 17:00:00
|Time Zone : (Brussels time)|
Topic DescriptionSpecific Challenge:
EU demographic change requires innovation to enhance active ageing, whereby a growing market for osteoarticular tissue regeneration is created. To reduce patients’ sufferings, mitigate the economic burdens to health systems and exploit market opportunities it is crucial to conceive innovative designs and development of innovative biomaterials that enables the delivery of smart, nanostructured and functionalised tissues to regenerate and integrate bones, cartilages, tendons and joints.Scope:
To design and develop user-centred innovative and smart nanobiomaterials which may be also adaptable to remote control, that will lead to a personalised regeneration of osteoarticular tissues (bones, cartilages, tendons, joints). The nanobiomaterials should be designed to perform in host tissues affected by severe degenerative and/or inflammatory processes, which typically characterise Osteoarticular pathologies. Proposals should cover at least one of the following technologies, leading to a convergence of processes:
(i) 3D-bioprinting; (ii) stem cells seeding, recruiting, activation, functionalisation, and cell printing; (iii) nano functionalisation; (iv) 3D-printable biophoto-polymerisation; (v) use of light to expose/mask tethered signalling molecules, incorporating immune-modulatory materials such as complement regulators; (vi) additive manufacturing by laser sintering, rapid prototyping technologies, stereolithography, inkjet techniques; (vii) relevant cross-cutting KETs; (viii) electrospinning.
The research design should be developed by means of a multidisciplinary approach and involve relevant stakeholders. As relevant, proposals should consider sex and gender specific aspects.
Proposals submitted under this topic should include actions designed to facilitate cooperation with other projects; to enhance user involvement; and to ensure the accessibility and reusability of data produced in the course of the project.
Activities should start at TRL 3 and achieve TRL 5 at the end of the project.
The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.Expected Impact:
- Alleviate heavy burdens on patients and healthcare systems by developing smart nano-engineered affordable biomaterials for tissue self-healing and regeneration; improve the well-being, health, quality of life and active ageing of populations;
- Boost industrial competitiveness and leadership of EU companies in personalised bio-intelligent materials responding to patients' clinical specificities;
- Enhanced incorporation of digitalisation and Internet of Things for innovative and affordable biomaterials;
- Increase EU attractiveness for the clinical development of regenerative medicine;
- reinforce the EU sector ecosystem to generate new markets and opportunities for SMEs, translating innovative biomaterials into pre-clinical tests for market uptake.
Relevant indicators and metrics, with baseline values, should be clearly stated in the proposal.Cross-cutting Priorities:
Topic conditions and documents
1. Eligible countries: described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
- Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
- Submission and evaluation processes are described in the Online Manual.
The following exceptions apply:
Under 3 (a) Proposals are first ranked in separate lists according to the topics against which they were submitted (‘topic ranked lists’). When comparing ex aequo proposals from different topics, proposals having a higher position in their respective 'topic ranked list' will be considered to have a higher priority in the overall ranked list.
Under 3 (b) For all topics and types of action, the prioritisation will be done first on the basis of the score for Impact, and then on that for Excellence.
The threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (two-stage call):
For stage 1: maximum 3 months from the deadline for submission.
For stage 2: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
6. Additional provisions:
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
8. Additional documents:
1. Introduction WP 2018-20
5. Introduction to Leadership in enabling and industrial technologies (LEITs) WP 2018-20
5ii. Nanotechnologies, advanced materials, advanced manufacturing and processing, biotechnology WP 2018-20
- FLASH CALL INFO en
No submission system is open for this topic.
H2020 Online Manual is your guide on the procedures from proposal submission to managing your grant.
Participant Portal FAQ – Submission of proposals.
National Contact Points (NCP) - contact your NCP for further assistance in your national language(s).
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk - contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues
CEN and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at firstname.lastname@example.org
Partner Search Services help you find a partner organisation for your proposal.